Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction.
Addiction
Degradation
Drug design
Enzyme
Enzyme catalysis
Metabolism
Nicotine
Nicotine-degrading enzyme
Protein engineering
Smoking cessation
Journal
BMC biotechnology
ISSN: 1472-6750
Titre abrégé: BMC Biotechnol
Pays: England
ID NLM: 101088663
Informations de publication
Date de publication:
02 08 2019
02 08 2019
Historique:
received:
09
05
2019
accepted:
23
07
2019
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Smoking and tobacco use continue to be the largest preventable causes of death globally. A novel therapeutic approach has recently been proposed: administration of an enzyme that degrades nicotine, the main addictive component of tobacco, minimizing brain exposure and reducing its reinforcing effects. Pre-clinical proof of concept has been previously established through dosing the amine oxidase NicA2 from Pseudomonas putida in rat nicotine self-administration models of addiction. This paper describes efforts towards optimizing NicA2 for potential therapeutic use: enhancing potency, improving its pharmacokinetic profile, and attenuating immunogenicity. Libraries randomizing residues located in all 22 active site positions of NicA2 were screened. 58 single mutations with 2- to 19-fold enhanced catalytic activity compared to wt at 10 μM nicotine were identified. A novel nicotine biosensor assay allowed efficient screening of the many primary hits for activity at nicotine concentrations typically found in smokers. 10 mutants with improved activity in rat serum at or below 250 nM were identified. These catalytic improvements translated to increased potency in vivo in the form of further lowering of nicotine blood levels and nicotine accumulation in the brains of Sprague-Dawley rats. Examination of the X-ray crystal structure suggests that these mutants may accelerate the rate limiting re-oxidation of the flavin adenine dinucleotide cofactor by enhancing molecular oxygen's access. PEGylation of NicA2 led to prolonged serum half-life and lowered immunogenicity observed in a human HLA DR4 transgenic mouse model, without impacting nicotine degrading activity. Systematic mutational analysis of the active site of the nicotine-degrading enzyme NicA2 has yielded 10 variants that increase the catalytic activity and its effects on nicotine distribution in vivo at nicotine plasma concentrations found in smokers. In addition, PEGylation substantially increases circulating half-life and reduces the enzyme's immunogenic potential. Taken together, these results provide a viable path towards generation of a drug candidate suitable for human therapeutic use in treating nicotine addiction.
Sections du résumé
BACKGROUND
Smoking and tobacco use continue to be the largest preventable causes of death globally. A novel therapeutic approach has recently been proposed: administration of an enzyme that degrades nicotine, the main addictive component of tobacco, minimizing brain exposure and reducing its reinforcing effects. Pre-clinical proof of concept has been previously established through dosing the amine oxidase NicA2 from Pseudomonas putida in rat nicotine self-administration models of addiction.
RESULTS
This paper describes efforts towards optimizing NicA2 for potential therapeutic use: enhancing potency, improving its pharmacokinetic profile, and attenuating immunogenicity. Libraries randomizing residues located in all 22 active site positions of NicA2 were screened. 58 single mutations with 2- to 19-fold enhanced catalytic activity compared to wt at 10 μM nicotine were identified. A novel nicotine biosensor assay allowed efficient screening of the many primary hits for activity at nicotine concentrations typically found in smokers. 10 mutants with improved activity in rat serum at or below 250 nM were identified. These catalytic improvements translated to increased potency in vivo in the form of further lowering of nicotine blood levels and nicotine accumulation in the brains of Sprague-Dawley rats. Examination of the X-ray crystal structure suggests that these mutants may accelerate the rate limiting re-oxidation of the flavin adenine dinucleotide cofactor by enhancing molecular oxygen's access. PEGylation of NicA2 led to prolonged serum half-life and lowered immunogenicity observed in a human HLA DR4 transgenic mouse model, without impacting nicotine degrading activity.
CONCLUSIONS
Systematic mutational analysis of the active site of the nicotine-degrading enzyme NicA2 has yielded 10 variants that increase the catalytic activity and its effects on nicotine distribution in vivo at nicotine plasma concentrations found in smokers. In addition, PEGylation substantially increases circulating half-life and reduces the enzyme's immunogenic potential. Taken together, these results provide a viable path towards generation of a drug candidate suitable for human therapeutic use in treating nicotine addiction.
Identifiants
pubmed: 31375100
doi: 10.1186/s12896-019-0551-5
pii: 10.1186/s12896-019-0551-5
pmc: PMC6679477
doi:
Substances chimiques
Bacterial Proteins
0
Nicotine
6M3C89ZY6R
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Subventions
Organisme : National Institute on Drug Abuse
ID : R43 DA044064
Pays : United States
Références
Psychopharmacology (Berl). 1999 Apr;143(2):150-7
pubmed: 10326777
J Appl Toxicol. 1999 Jul-Aug;19(4):261-6
pubmed: 10439340
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12493-7
pubmed: 11050152
Psychopharmacology (Berl). 2002 Feb;160(1):56-66
pubmed: 11862374
J Abnorm Psychol. 2003 Feb;112(1):3-13
pubmed: 12653409
J Abnorm Psychol. 2003 Feb;112(1):14-27
pubmed: 12653410
Psychopharmacology (Berl). 2003 Aug;169(1):68-76
pubmed: 12774186
Exp Clin Psychopharmacol. 2003 Nov;11(4):276-85
pubmed: 14599261
Pharmacol Rev. 2005 Mar;57(1):79-115
pubmed: 15734728
Neuropsychopharmacology. 2006 Jun;31(6):1203-11
pubmed: 16192981
Psychopharmacology (Berl). 2006 Mar;184(3-4):353-66
pubmed: 16240165
Psychopharmacology (Berl). 2006 Mar;184(3-4):391-400
pubmed: 16249908
Psychopharmacology (Berl). 2007 Feb;190(3):353-62
pubmed: 16847680
Neuropharmacology. 2007 Mar;52(3):985-94
pubmed: 17157884
Trends Pharmacol Sci. 2007 Mar;28(3):135-41
pubmed: 17276521
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68
pubmed: 18640919
Annu Rev Pharmacol Toxicol. 2009;49:57-71
pubmed: 18834313
Comput Methods Programs Biomed. 2010 Sep;99(3):306-14
pubmed: 20176408
Arch Biochem Biophys. 2010 Jun 15;498(2):83-8
pubmed: 20417173
J Bacteriol. 2011 Oct;193(19):5541-2
pubmed: 21914868
PLoS One. 2012;7(12):e52031
pubmed: 23284860
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
FEBS Lett. 2013 Sep 2;587(17):2753-66
pubmed: 23850893
Nat Immunol. 2014 Feb;15(2):128-35
pubmed: 24448570
Arthritis Res Ther. 2014 Mar 04;16(2):R60
pubmed: 24588936
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
J Am Chem Soc. 2015 Aug 19;137(32):10136-9
pubmed: 26237398
J Appl Toxicol. 2016 May;36(5):669-84
pubmed: 26251951
Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):135-40
pubmed: 2682399
Biochemistry. 2016 Dec 6;55(48):6595-6598
pubmed: 27933790
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Biochemistry. 2018 Jul 3;57(26):3741-3751
pubmed: 29812904
BMC Biotechnol. 2018 Jul 24;18(1):46
pubmed: 30041697
Sci Adv. 2018 Oct 17;4(10):eaat4751
pubmed: 30345354
Psychol Rev. 1974 Mar;81(2):119-45
pubmed: 4817611
J Chromatogr. 1981 Jan 2;222(1):61-70
pubmed: 6783675
J Immunol Methods. 1995 Oct 12;186(1):37-46
pubmed: 7561146
FEBS Lett. 1993 Feb 8;317(1-2):152-6
pubmed: 8428624
J Exp Med. 1996 Jun 1;183(6):2635-44
pubmed: 8676084
Anal Biochem. 1997 Nov 15;253(2):169-74
pubmed: 9367499
J Pharmacol Exp Ther. 1997 Dec;283(3):1076-81
pubmed: 9399979